Biosimilar

Amjevita, Cigna’s adalimumab biosimilar that made its U.S. marketplace debut in January, has so far failed to make an impact among patients compared with the reference drug, according to a physician survey.

Coherus BioSciences’ adalimumab biosimilar, Yusimry, will make its debut in the U.S. marketplace this summer at an 85% discount compared with the originator Humira, according to the manufacturer.

CHICAGO — Subcutaneous maintenance therapy with an infliximab biosimilar after IV induction resulted in sustained clinical remission and greater endoscopic response vs. placebo in patients with moderate to severe Crohn’s disease.

The FDA has approved Celltrion USA’s Yuflyma as the ninth biosimilar to adalimumab for all eligible indications of the reference product, and the latest in a flood of biosimilars cleared for 2023 release in the United States.

DESTIN, Fla. — There are myriad advantages to an increased availability of lower-cost biosimilar therapies in rheumatology, according to a speaker at the 2023 Congress of Clinical Rheumatology meeting.

Patients with rheumatoid arthritis who receive an etanercept biosimilar demonstrate similar disease activity and survival outcomes as those who receive the originator product, according to data published in Rheumatology.

In this Healio exclusive video, Jashin J. Wu, MD, FAAD, of the University of Miami Miller School of Medicine, discusses his American Academy of Dermatology Annual Meeting presentation on biologics and biosimilars in psoriasis treatment.

A collection of new presenters will be speaking at the 2023 Congress of Clinical Rheumatology-East, covering biosimilars and complex diseases under the rheumatology umbrella, including sarcoidosis and Sjögren’s syndrome.

The FDA has denied a biologics license application to Alvotech for AVT02, a high-concentration adalimumab biosimilar candidate, according to a press release from Teva Pharmaceutical Industries.

Oncology drug costs overall, and immunotherapy costs specifically, drove Medicare spending increases for outpatient end-of-life cancer care, according to research in International Journal of Radiation Oncology, Biology, Physics.